Corticosteroid-associated avascular necrosis: dose relationships and early diagnosis

被引:33
作者
Aaron, Roy K. [1 ]
Voisinet, Anne [1 ]
Racine, Jennifer [1 ]
Ali, Yousaf [2 ]
Feller, Edward R. [3 ]
机构
[1] Brown Univ, Warren Alpert Med Sch, Dept Orthopaed, Providence, RI 02912 USA
[2] Mt Sinai Sch Med, Dept Med, New York, NY USA
[3] Brown Univ, Warren Alpert Med Sch, Dept Community Med, Providence, RI 02912 USA
来源
SKELETAL BIOLOGY AND MEDICINE II: BONE AND CARTILAGE HOMEOSTASIS AND BONE DISEASE | 2011年 / 1240卷
关键词
Corticosteroids; avascular necrosis; systemic lupus erythematosus; renal transplant; SYSTEMIC-LUPUS-ERYTHEMATOSUS; FEMORAL-HEAD; ANTIPHOSPHOLIPID ANTIBODIES; RENAL-TRANSPLANTATION; RISK-FACTORS; NONTRAUMATIC NECROSIS; INDUCED OSTEONECROSIS; ASEPTIC NECROSIS; SILENT HIP; BONE;
D O I
10.1111/j.1749-6632.2011.06218.x
中图分类号
R5 [内科学];
学科分类号
100201 [内科学];
摘要
Corticosteroids are the most common etiological factor in nontraumatic avascular necrosis (AVN) of bone, accounting for about 10% of arthroplasties performed annually in the United States. Evidence is conflicting on the relative importance of peak dose, daily dose, or cumulative dose, and most likely all three represent "high dose" corticosteroid administration and play a role in AVN. The etiology may be multifactorial with corticosteroids superimposed on genetic or pathological predispositions. Joint preservation depends upon early diagnosis and treatment before fracture of the subchondral trabeculae and joint incongruity. Early intervention depends upon identifying at-risk patients and quantifying their risk by understanding clinical and pathophysiological contributions to that risk. Our data and that of others suggest that a screening MRI of at-risk populations will permit detection of AVN at a prefracture stage when preservation of the joint is possible.
引用
收藏
页码:38 / 46
页数:9
相关论文
共 74 条
[1]
Aaron R.K., 1997, ETIOLOGY DIAGNOSIS M, P261
[2]
Aaron R.K., 2011, COAGULAPOTHIES AVASC
[3]
AARON RK, 1989, CLIN ORTHOP RELAT R, P209
[4]
Aaron RK, 2001, CURR OPIN ORTHOP, V12, P378, DOI DOI 10.1097/00001433-200110000-00003
[5]
Aaron RK, 2001, TECH ORTHOP, V16, P1
[6]
Aaron RK, 2007, ADULT HIP, P465
[7]
Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study [J].
Agarwala, S ;
Jain, D ;
Joshi, VR ;
Sule, A .
RHEUMATOLOGY, 2005, 44 (03) :352-359
[8]
ASHERSON RA, 1993, J RHEUMATOL, V20, P284
[9]
ATSUMI T, 1992, CLIN ORTHOP RELAT R, P22
[10]
SUBCAPITAL FRACTURES OF FEMUR [J].
BARNES, R ;
BROWN, JT ;
GARDEN, RS ;
NICOLL, EA .
JOURNAL OF BONE AND JOINT SURGERY-BRITISH VOLUME, 1976, 58 (01) :2-24